NewsBenzingaSELLAS Life Sciences To Present Data From Completed Phase 2 Study Of SLS009 For Treatment Of R/R AML, At 68th ASH Annual Meeting And Exposition SELLAS Life Sciences To Present Data From Completed Phase 2 Study Of SLS009 For Treatment Of R/R AML, At 68th ASH Annual Meeting And Exposition Benzinga 2026.11.04 14:04 (GMT+0) Open on Benzinga Other news Nvidia Unveils Rubin HPC GPU for Scientific Computing Solana Foundation Issues Urgent Security Alert: Linux Kernel Vulnerability Should Be Patched as Soon as Possible DTCC, Barclays Say Tokenization's Real Prize Is Unlocking Idle Collateral Novo Nordisk vs. Amgen: 1 Has the Blockbuster Weight-Loss Drugs, the Other Has a Promising Rival Cathie Wood and Jim Cramer Disagree on Nvidia Stock Without Jensen Huang. Earnings Could Decide Who's Right A $1.3 Billion Reason to Buy Firefly Aerospace Stock Here
Solana Foundation Issues Urgent Security Alert: Linux Kernel Vulnerability Should Be Patched as Soon as Possible
Cathie Wood and Jim Cramer Disagree on Nvidia Stock Without Jensen Huang. Earnings Could Decide Who's Right